Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT05817955RecruitingPhase 2
Azacitidine plus ruxolitinib for higher-risk MDS/MPN
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
Nanjing, JiangsuAges 18–80 - NCT05757245RecruitingPhase 1
Safety and effectiveness of GMCN-508A for transfusion-dependent alpha thalassemia
This Phase 1 study tests a new medicine (GMCN-508A) to see how safe it is and whether it can help people with transfusion-dependent alpha thalassemia. Participants are also expected to follow a treatment plan that includes stem cell transplantation preparation.
Nanning, GuangxiAges 5–35 - NCT05804643Recruiting
MRI scans to study swelling from breast cancer
This study uses special MRI (a detailed body scan) to better evaluate arm or hand swelling caused by breast-cancer–related lymphedema. It may help doctors understand how to measure lymphedema more accurately.
TaipeiAges 20 years+ - NCT05832580RecruitingPhase 3
Preventing calcium buildup in skin, eyes, and blood vessels
This Phase 3 study tests a medicine to help prevent abnormal calcium (called ectopic mineralization) from building up in people with pseudoxanthoma elasticum (PXE). It aims to slow or reduce new damage over time.
UtrechtAges 18–50 - NCT04920474Recruiting
Share blood and transplant samples for future research
This study builds a library of transplant and related medical samples to help scientists learn how to improve cell therapies and care for marrow injury. You may be included because you are a donor, receive a transplant or cell therapy, or are treated for marrow toxic injury at participating centers.
New Brighton, MinnesotaAges Any age - NCT05840575Recruiting
Study of thinking changes in young people during cancer treatment
This study looks at how thinking and memory may change in children and young adults after a new cancer diagnosis, especially around chemotherapy. It may help doctors better understand and track brain-related side effects early.
CopenhagenAges 7–29 - NCT05831865Recruiting
Testing best first-line stem cell transplant for aggressive lymphoma
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Beijing, Beijing MunicipalityAges 18–70 - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05762510RecruitingEarly Phase 1
Testing a gene-based treatment for transfusion-dependent thalassemia
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
Nanning, GuangxiAges 5–35 - NCT05392894RecruitingPhase 3
Transplant using a half-matched donor for severe sickle cell
This trial tests whether a half-matched (haploidentical) blood stem cell transplant can treat adults with severe sickle cell disease. It may help reduce serious complications and improve survival, but it requires a fit health status and specific donor and medical conditions.
LondonAges 18 years+ - NCT05853796Recruiting
Studying stroke warning signs in young adults
This observational study follows people ages 18–50 who had a first TIA (“mini-stroke”) or an acute ischemic stroke to better understand what happens after the event. It may help improve future care by tracking symptoms, imaging findings, and recovery over time.
Nijmegen, GelderlandAges 18–50 - NCT03125707Recruiting
Registry for adults with certain BCR-ABL1–negative blood cancers
This study keeps a patient registry to collect information about people with specific myeloid blood neoplasms (a type of blood cancer). It helps researchers understand these conditions over time and may improve how patients are cared for in the future.
AugsburgAges 18 years+ - NCT05846763Recruiting
Obinutuzumab plus lenalidomide for returning follicular lymphoma
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
TianjinAges 18 years+ - NCT05882773Recruiting
Registry for adults with certain blood cancers
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
Hong KongAges 18 years+ - NCT05899621Recruiting
Study of obinutuzumab-based treatment for untreated follicular lymphoma
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05909293Recruiting
Venetoclax maintenance for older adults with AML in remission
This study tests whether “maintenance” treatment with venetoclax can help older adults with acute myeloid leukemia (AML) stay in remission after initial therapy. It may help delay the return of AML, especially in people who achieved first complete remission.
Nanjing, JiangsuAges 60–85 - NCT05924347Recruiting
Imaging study to spot early spine changes in at-risk children
This study uses MRI and physical measurements to look for early signs of scoliosis (a side-bending of the spine) in children who are at higher risk. It may help doctors understand when scoliosis starts and improve early monitoring.
UtrechtAges 8–11 - NCT05931263RecruitingPhase 3
Tested Chi-BEAM vs BEAM before stem cell transplant for lymphoma
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Nanjing, JiangsuAges 18–65 - NCT05802836Recruiting
Tracking an antibody response in severe hemophilia A on emicizumab
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
Frankfurt am Main, HesseAges Any age - NCT05937828Recruiting
Caring for children with autoimmune blood disorders in France
This study follows children and teens who have certain autoimmune blood conditions to better understand their illness. It may help doctors learn how these conditions behave over time and improve care.
AmiensAges Up to 17 years - NCT05937880Recruiting
Leflunomide for kids with stubborn Henoch-Schonlein purpura rash
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
Guangzhou, GuangdongAges 1–18 - NCT05965115Recruiting
Screening study for family members of multiple myeloma patients
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05948033RecruitingPhase 1/Phase 2
CD70-targeted CAR-T for relapsed lymphoma with CD70
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT05950750Recruiting
Living with aTTP? Join a national patient registry study
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
AnkaraAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.